RxDoctor Payments Data

Christopher Norton

Physician Assistant · Placerville, CANPI 1033560784

Payments from drug & device makers

$4,983in general payments, 2019–2025

Across 253 payments — averaging $19.70 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Johnson & Johnson$900
  • AbbVie$764
  • Lilly USA, LLC$638
  • Sanofi$495
  • E.r. Squibb & Sons, L.L.C.$424
  • Sun Pharmaceutical Industries Inc.$402
  • plus $1K from 12 others

What the payments were for

  • Food & beverage$4,37588%
  • Education$60812%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$4,983 in reported general payments places this provider in the 90th percentile of 10,423 physician assistant providers in California.

See all physician assistant providers in California

Medicare billing

Part B allowed, 2024
$48,444
Medicare patients
173
Services billed
896

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
Dupixent PenDupilumab16$67,965
OtezlaApremilast12$57,178
Ketoconazole304$5,075
Fluorouracil69$4,273
Fluocinonide110$3,987
Clobetasol Propionate39$2,350
Calcipotriene14$1,559
Triamcinolone Acetonide121$846
Ciclopirox29$778
Mupirocin98$723
ValacyclovirValacyclovir Hcl17$684
Fluocinolone Acetonide14$618
Betamethasone Dipropionate14$614
Doxycycline Hyclate14$529
Hydrocortisone77$399

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
AmgenOtezla$149$57,17812 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 90th percentile of 10,423 physician assistant providers in California.

Other physician assistant in Placerville

See the full list for California

Where these figures come from

Is this you, or does something look wrong? →